Clinical Trial Update: MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016) [Phase 2]

View source ↗

Summary

Phase 2 trial MK0767 for metabolic syndrome with dyslipidemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Metabolic Syndrome

Drugs mentioned

• MK0767

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metabolic X Syndrome Dyslipidemia | Phase 2 | Status: TERMINATED